• Welcome to WindMIL
    A platform for cell-based immuno-oncology therapy

About

WHAT WINDMIL Therapeutics® DOES

At WindMIL, we are harnessing the power of bone marrow derived lymphocytes to develop ground-breaking immunotherapies to treat cancer patients. We have perfected an efficient and rapid process to extract, activate and expand bone marrow derived T cells. The result of this process is called Marrow Infiltrating Lymphocytes or MILsTM. Owing to their derivation from the bone marrow, which is a natural reservoir for memory T cells, MILsTM have unique properties that make them well suited for application in autologous cell therapy. Our lead program is in a Phase 2b study in high-risk multiple myeloma with additional programs in solid tumors using MILsTM advancing to the clinic. We are also advancing programs to supercharge MILs through genetic-modification.

Technology

WHAT MAKES MILS SPECIAL

MILsTM represent a novel class of cell therapy. While the vast majority of cell therapy approaches rely on lymphocytes derived from the periphery, MILsTM are derived from the bone marrow. This is important, because, put simply, in cell therapy…cell source matters. The bone marrow is a natural reservoir for memory T cells. WindMIL’s founders were among the first to describe the presence of tumor-specific memory T cells in the marrow of cancer patients. Producing MILsTM from this cell source results in a cell therapy product with several unique features including:

• Inherent tumor specificity
• Maximal cytotoxicity due to memory phenotype
• Long persistence

Pipeline

WHAT WINDMIL IS WORKING ON

Unmodified MILs

The specificity inherent in the native TCRs of the T cells that form MILsTM eliminates the need for genetic modification entirely. This freedom has proven both to lower manufacturing cost and lower toxicity. It also eliminates the need to pre-identify a tumor-specific antigen, something that has proven difficult in solid tumors in particular.

Unmodified MILs are currently being studied in a randomized, multi-center, Phase II trial in high risk multiple myeloma. WindMiL also plans to open additional trials in solid tumors in the near future.

MIL CARs

Bone-marrow derived memory T cells are known to be the body’s most effective generators of a cytotoxic response and are highly persistent. These two features make MILsTM the ideal cell source from which to create CAR-T cells. Furthermore, the native TCR of MILsTM should allow recognition of the tumor even if the cognate antigen of the CAR is no longer expressed by the tumor.

MIL CARs are currently in preclinical development.

genMILs

WindMIL is also investigating a variety of proprietary genetic modifications to MILsTM. For instance, we believe certain proprietary genetic modifications may make MILsTM capable of functioning in highly suppressive tumor microenvironments.

genMILs are currently in preclinical development.

MEET OUR TEAM

THE EXPERTS THAT DRIVE WINDMIL

CONTACT

Reach out to Windmil

  • 1812 Ashland Avenue, 1st Floor, Suite 100, Baltimore, MD 21205
  • 410-558-1906